📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longitudinal study. (2023)

First Author: Rodziewicz M

Attributed to: MICA: The North West England MRC Fellowship Scheme in Clinical Pharmacology and Therapeutics funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s2665-9913(23)00091-7

PubMed Identifier: 38251591

Publication URI: http://europepmc.org/abstract/MED/38251591

Type: Journal Article/Review

Volume: 5

Parent Publication: The Lancet. Rheumatology

Issue: 5

ISSN: 2665-9913